Update on PET Tracer Development for Muscarinic Acetylcholine Receptors

Marius Ozenil, Jonas Aronow, Marlon Millard, Thierry Langer, Wolfgang Wadsak, Marcus Hacker, Verena Pichler

TL;DR

This review highlights the ongoing challenges and recent progress in developing Positron Emission Tomography (PET) tracers for muscarinic acetylcholine receptors (mAChRs). The development of selective and effective mAChR PET tracers is crucial for understanding neurodegenerative diseases and advancing drug development, but faces hurdles like blood-brain barrier penetration and subtype selectivity.

What Problem Does This Paper Address?

The muscarinic acetylcholine receptor (mAChR) system plays a vital role in regulating numerous functions in both the central and peripheral nervous systems, making it a significant therapeutic target for conditions like neurodegenerative diseases. To effectively monitor disease progression, understand mAChR roles in disease, and clarify their complex functions, clinically applicable PET tracers are essential. However, despite decades of research, no mAChR PET tracer has achieved widespread clinical use. This gap stems from challenges in designing tracers that can effectively penetrate the blood-brain barrier (BBB), exhibit high target affinity and selectivity, and possess favorable pharmacokinetic properties. This review aims to summarize the strategies, challenges, and recent advancements in developing these crucial imaging agents.

Methods

This paper is a review, synthesizing existing research on mAChR PET tracer development. It discusses various strategies employed in designing these tracers, including:

  • Ligand Design: Exploring orthosteric, allosteric, and bitopic ligand approaches to achieve subtype selectivity and high affinity.
  • Radiochemistry: The importance of facile radiolabeling, particularly with short-lived isotopes like Carbon-11 and Fluorine-18.
  • Physicochemical Properties: Emphasizing the critical role of properties like lipophilicity (logP) and topological polar surface area (tPSA) for BBB penetration.
  • Computational Approaches: Discussing the increasing use of in silico methods like molecular docking and quantitative structure-activity relationships (QSAR) to predict tracer behavior and guide design.
  • Preclinical and Clinical Evaluation: Reviewing how developed tracers are assessed through in vitro binding assays, ex vivo autoradiography, in vivo imaging in animal models, and, where available, human studies.

Datasets

Not discussed in the paper. The paper focuses on reviewing existing research and does not introduce new datasets or benchmarks.

Key Insights and Ideas

  • The "Holy Grail" of mAChR Imaging: Developing PET tracers that are not only highly selective for specific mAChR subtypes but also possess excellent brain penetration and minimal non-specific binding remains a significant challenge.
  • Subtype Selectivity is Key: The five mAChR subtypes (M1-M5) have distinct roles, and understanding these requires tracers that can differentiate between them. However, the structural similarity of their orthosteric binding pockets makes achieving this selectivity difficult.
  • Beyond Affinity: Kinetics Matter: While high affinity is crucial, a slow off-rate can hinder accurate imaging. Understanding binding kinetics is becoming increasingly important for successful tracer development.
  • Allosteric and Bitopic Ligands as Game Changers: Recent advances in understanding allosteric binding sites and the development of bitopic ligands (binding to both orthosteric and allosteric sites) offer promising avenues for achieving higher subtype selectivity.
  • Computational Tools are Gaining Traction: In silico methods are becoming indispensable for predicting BBB permeability, non-specific binding, and guiding the design of novel tracer candidates, potentially reducing the time and cost of experimental screening.
  • Peripheral mAChR Imaging is Under-Explored: While most research focuses on the CNS, mAChRs are also crucial in peripheral systems, and developing PET tracers for these targets could have significant implications, especially with the advent of full-body PET scanners.

Key Results

The paper reviews numerous mAChR PET tracer candidates developed over the past few decades. While many have shown promise in preclinical studies, few have translated to widespread clinical use. Key findings from the review include:

  • Early SPECT tracers (e.g., [123I]IQNB) were foundational but lacked subtype selectivity and had limitations in resolution and sensitivity.
  • Carbon-11 labeled tracers (e.g., [11C]scopolamine, [11C]NMPB) have been extensively studied but often suffer from flow-dependent distribution and limited subtype selectivity.
  • Fluorine-18 labeled tracers (e.g., [18F]4-FDEX, [18F]FP-TZTP) offer longer half-lives, potentially aiding in overcoming flow-dependency, but still face challenges in achieving high subtype selectivity.
  • Recent developments have focused on allosteric (e.g., [11C]GSK1034702) and bitopic ligands, showing improved subtype selectivity (e.g., M1, M4 selective tracers like [11C]LSN3172176 and [11C]MK-6884).
  • No tracers targeting M3 or M5 subtypes are reported to be in even early stages of development, highlighting a significant gap.

Limitations and Future Work

The authors acknowledge several limitations and challenges in mAChR PET tracer development:

  • Flow-dependent tracer accumulation: This remains a significant hurdle, impacting accurate quantification of receptor density.
  • Limited specific binding: Many tracers exhibit substantial non-specific binding, reducing the signal-to-noise ratio.
  • Metabolic instability: Rapid metabolism of tracers in vivo can lead to inaccurate results.
  • BBB penetration: Designing tracers that efficiently cross the BBB while maintaining target affinity is a constant challenge.
  • Subtype selectivity: Achieving high selectivity for individual mAChR subtypes is difficult due to structural similarities.
  • Lack of M3 and M5 tracers: Future work should focus on developing ligands targeting these under-represented subtypes.
  • Peripheral mAChR imaging: Further development is needed for tracers that can effectively image mAChRs in peripheral organs.
  • Advancement of computational methods: Continued development and application of in silico tools are crucial for rational tracer design.
  • Exploration of longer-lived radionuclides: Investigating PET nuclides with longer half-lives could help mitigate flow-dependent issues.

Summary updated

Abstract

The muscarinic cholinergic system regulates peripheral and central nervous system functions, and, thus, their potential as a therapeutic target for several neurodegenerative diseases is undoubted. A clinically applicable positron emission tomography (PET) tracer would facilitate the monitoring of disease progression, elucidate the role of muscarinic acetylcholine receptors (mAChR) in disease development and would aid to clarify the diverse natural functions of mAChR regulation throughout the nervous system, which still are largely unresolved. Still, no mAChR PET tracer has yet found broad clinical application, which demands mAChR tracers with improved imaging properties. This paper reviews strategies of mAChR PET tracer design and summarizes the binding properties and preclinical evaluation of recent mAChR tracer candidates. Furthermore, this work identifies the current major challenges in mAChR PET tracer development and provides a perspective on future developments in this area of research.
BibTeX
@inproceedings{ozenil2021update,
  author = {Marius Ozenil and Jonas Aronow and Marlon Millard and Thierry Langer and Wolfgang Wadsak and Marcus Hacker and Verena Pichler},
  title = {{Update on PET Tracer Development for Muscarinic Acetylcholine Receptors}},
  booktitle = {Pharmaceuticals},
  year = {2021},
  doi = {10.3390/ph14060530},
}
Figure